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Abstract 
The burden of human diseases in populations, or for an individual, is frequently estimated in terms 
of one of a number of Health Adjusted Life Years (HALYs). The Disability Adjusted Life Year 
(DALY) is a widely accepted HALY metric and is used by the World Health Organization and the 
Global Burden of Disease studies. Many human diseases are of animal origin and often cause ill 
health and production losses in domestic animals. The economic losses due to disease in animals are 
usually estimated in monetary terms. The monetary impact on animal health is not compatible with 
HALY approaches used to measure the impact on human health. To estimate the societal burden of 
zoonotic diseases that have substantial human and animal disease burden we propose methodology 
which can be accommodated within the DALY framework. Monetary losses due to the animal 
disease component of a zoonotic disease can be converted to an equivalent metric using a local 
gross national income per capita deflator. This essentially gives animal production losses a time 
trade-off for human life years. This is the time required to earn the income needed to replace that 
financial loss. This can then be assigned a DALY equivalent, termed animal loss equivalents 
(ALE), and added to the DALY associated with human ill health to give a modified DALY. This is 
referred to as the “zDALY”. ALEs could also be estimated using willingness-to-pay for animal 
health or survey tools to estimate the replacement time value for animals with high societal or 
emotional value (for example pets) that cannot be calculated directly using monetary worth. Thus 
the zDALY estimates the impact of a zoonotic disease to animal and human health. The losses due 
to the animal disease component of the modified DALY are straightforward to calculate. A number 
of worked examples such as echinococcosis, brucellosis, Q fever and cysticercosis from a diverse 
spectrum of countries with different levels of economic development illustrate the use of the 
zDALY indicator.  
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Introduction 
An understanding of the economic and social impacts of diseases is central to the decision making 
process for disease control. Animal disease impact is widely studied using economic models based 
on monetary costs[1-3]. Therefore animal losses can be estimated for the values of livestock and 
livestock products lost through diseases[4,5]. In health economics the cost of human disease can be 
quantified in terms of cost of treatment and loss of income during convalescence in cost of illness 
studies[6,7]. For example in the Netherlands the cost of illness for 14 food-related pathogens for 
2011 was estimated at approximately €468 million[8]. These costs included several zoonoses such 
as toxoplasmosis, which had costs of approximately €55 million. 
The calculation of a monetary burden of human ill health, to incorporate death and disability 
as well as the cost of illness, has been criticised for a number of reasons. There is no standard 
methodology to calculate the monetary value of life (or loss due to premature death) resulting in 
great variability amongst different studies[9]. This also varies with per capita income, with the lives 
of individuals from high income countries being assigned, on average, a greater monetary value. 
Indeed, this has been modelled to estimate the statistical value of life with gross domestic product 
per capita as a covariate[10]. Likewise, costs of medical treatment and loss of wages are usually 
higher in upper than in lower income countries. This could perversely suggest that the greatest 
economic impact of disease is in wealthy countries, despite having higher life expectancies and 
lower disease incidence than low income countries. Thus estimations of the monetary cost of 
disease effectively assign higher values to equivalent health outcomes in higher income countries  
than to the same outcomes in the low income countries[11]. 
Because of these and the wider issues around valuing human life, non-monetary population 
health metrics such as disability adjusted life years (DALYs) have been developed to quantify the 
burden of premature death and disease and injury[12]. DALYs are calculated by adding the number 
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of years lived with disability adjusted for the severity of the disease (YLDs) and the number of 
years of life lost due to premature mortality (YLLs)[13]. DALYs have been adopted by the WHO to 
quantify the global burden of disease[14] and the global burden of foodborne diseases[15]. They 
can also be used in cost-effectiveness studies such as cost per DALY averted, for example rabies in 
Kazakhstan[16].   
In the animal health field, there have been attempts to mirror these burden estimates for 
animal diseases.  There are important conceptual difficulties: how to compare within and across 
animal species, the fact that for livestock producers maximising their animals’ life expectancy is not 
necessarily a goal and that the same physical disabilities have very different outcomes in different 
livestock productions systems.  Work sponsored by the World Bank[17] assigned  livestock unit 
(LSU) values to different animal species, similar to the standard approach based on animal weights 
and mapped  the total units to be lost through death, destruction or slaughter.  Despite emphasizing 
the unevenness of and major gaps in the data available on livestock disease impact, this study did 
illustrate the relative geographical burden of fatal animal diseases. However, it assigned the same 
weight to animals of a single species across the world and did not quantify non-fatal outcomes – the 
production losses which undermine the profitability of livestock keeping in many situations. For 
example for echinococcosis, there are no reports of losses in China, India and much of the Middle 
East and North Africa in the World Bank Atlas yet these regions are highly endemic for 
Echinococcus granulosus[18].  By contrast, the well-established methods of animal health 
economics [3], allow for the impacts of animal disease, including trade effects and the cost of 
mitigating measures to reduce physical losses, to be estimated  in livestock across production 
systems and regions, and aggregated into a single currency.  By using willingness-to-pay and other 
household survey methods, the monetary value of companion animals and wildlife can be estimated 
in a range of contexts. As well as owners' valuations, financial awards in legal cases are often linked 
to the lifetime cost of keeping companion animals and for wildlife, other monetary considerations 
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include their commercial contribution to tourism. 
As a non-monetary value, DALYs do not capture other societal burdens that may not be 
directly human health-related. With zoonotic diseases there is clearly potential for a human disease 
and an animal disease burden, as by definition zoonoses infect both animals and humans[19]. 
Presently there has been no satisfactory metric developed that can incorporate both these burdens 
and estimate their relative share in the societal cost of disease. For zoonoses control projects, cost 
sharing in proportion to expected disease control benefits has been proposed[20], but this is related 
only to the estimated monetary benefits in terms of animal disease prevention and monetary savings 
from reduced cost of human illness, which are assessed separately from the DALY component. To 
be incorporated into the DALY metric, livestock deaths and production losses, need to be quantified 
into an animal disease burden metric which can stand alongside the DALY. Such a metric should 
reflect the impact of the animal disease on its owner in terms of the time that might be required to 
replace that animal or recoup the losses caused by its illness. Thus a subsistence farmer in sub-
Saharan Africa who loses a cow, of value $500, due to disease may suffer a much greater impact 
than a farmer from an industrialized nation who might lose a highly productive cow of value $1000. 
If the former has an income of just $1000 per annum and the latter $40,000 per annum, the relative 
time in terms of income generation to replace that loss would be six months for the former and 1.3 
weeks for the latter. The same approach can be extended to production losses from non-fatal animal 
diseases: if the same cow on a sub-Saharan African farm were to be infected with brucellosis it 
might suffer a 15% reduction in milk production and fertility[21] equivalent to, say, $75. In this 
case the African farmer would need nearly 4 weeks to replace that loss, whereas a farmer in an 
upper income country would require less than 1.5 days to replace a similar proportional loss.   
These impacts can thus be viewed as time that the livestock owner has been forced to 
sacrifice to replace the loss of his animal or to make up for the reduced output  that a non-fatal 
animal disease causes. In this manuscript we propose a modified DALY for zoonotic disease, 
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termed zDALY, that has an additional component, termed animal loss equivalents (ALE).  The 
ALE can be estimated from the monetary value of livestock losses and local per capita income by 
using a time trade-off approach to estimate an equivalent burden to the human population. The clear 
rationale is therefore to incorporate animal health losses into the DALY framework to assess the 
burden of diseases that transmit between animals and humans. In the DALY framework, non-fatal 
human illnesses and injuries are given a disability weight (DW) and the duration of this DW gives 
an equivalent number of lives lost and is essentially a time trade-off by assigning the time lived 
with the disability to a shorter time of healthy years (i.e. lived without the disability). It is proposed 
that the ALE component in the zDALY is also given a time equivalent of healthy years. A number 
of worked examples on different zoonotic diseases from low, middle and upper income countries 
are used to illustrate this concept. 
 
Materials and methods 
Data 
Cystic echinococcosis 
Human cystic echinococcosis (CE) is caused by the larval stage of E. granulosus. This results in a 
space occupying lesion, usually in the liver or lungs but occasionally affecting other organs such as 
the central nervous system. Most species of farm livestock can be infected with high prevalences 
frequently seen in sheep. CE can result in a substantial human disease burden and have a substantial 
economic impact on animal productivity[22,23]. In animals these include condemnation of edible 
offal, a lowered food conversion ratio and a decreased milk yield. The monetary value of these 
effects is used to estimate the ALE component of the zDALY. Both humans and livestock become 
infected by contact with infected dogs which are the definitive hosts of E. granulosus[24]. There are 
a number of estimates of the impact of CE in various countries including Iran[25], Jordan[26], 
Kyrgyzstan[27],  Peru[28], Spain[29]  and Tunisia[30].  The raw data, converted to 2015 US$ are 
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presented in Table 1.  
 
Brucellosis 
Human brucellosis is a zoonotic bacterial disease caused by a number of species of the genus  
Brucella. Human infection can result in intermittent fever, headaches, weakness, arthralgia, 
myalgia, weight loss, orchitis and spontaneous abortion[31]. In animals, brucellosis can cause a 
variety of clinical manifestations, particularly abortion, long run effects on fertility and reduced 
milk yield, resulting in substantial economic losses. These make up the ALEs contributing to the 
zDALY. Transmission to humans occurs through the consumption of infected, unpasteurized milk 
products, through direct contact with infected animal parts and through the inhalation of infected 
aerosolized particles[32]. Data on human brucellosis are officially reported figures from the Kyrgyz 
Ministry of Health[33]. Data for the economic impact of brucellosis in animals are based on 
Zinsstag et al.[21]. 
 
Q fever 
Q fever is caused by the bacterium Coxiella burnetti. Sheep, goats, and cattle are the primary 
reservoirs. The most common signs of Q fever in animals are abortion during late pregnancy or 
weak offspring[34]. This results in the economic losses in affected animals used to estimate ALEs 
and hence contribute to the zDALY. Infection of humans usually occurs by inhalation of bacteria or 
from ingestion of unpasteurized dairy products. Humans present with mild flu-like symptoms with 
occasional complications such as endocarditis. There was an epidemic of Q fever in the Netherlands 
with cases peaking in 2009[35]. The estimated economic costs of the outbreak and the burden of 
disease in terms of DALYs have been estimated[34,36].  
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Cysticercosis 
Taenia solium causes cysticercosis in pigs and neurocysticercosis in humans. The former can lead 
to substantial livestock losses whilst the latter can result in a number of neurological syndromes 
such as epilepsy[37]. Human cysticercosis results from faecal-oral contamination with T solium 
eggs from tapeworm carriers[38]. The dual monetary impact to animal production and human health 
burden in terms of DALYs has been estimated for West Cameroon[39]. Here it was assumed that 
infection with cysticercosis reduced the value of pigs by 30% and this was the basis for estimating 
the ALE component of the zDALY. The data from this report are used to estimate the number of 
zDALY due to T. solium cysticercosis.  
 
zDALY 
To calculate the zDALY, information on the incidence of human disease of interest together with 
the natural history of the disease and the morbidity and mortality rates are required. The degree of 
morbidity is required to estimate the DWs and the duration to estimate the YLDs[40]. Numbers of 
fatal cases, stratified by age are required for the YLLs. For the ALE component information about  
the morbidity and mortality in livestock or other domestic animals is required in addition to the 
local value of these animals and their  products. The income per head of the human population is 
also necessary to estimate a time trade-off for an economic loss due to animal disease. For animals 
that have no obvious commercial value, household survey methods, such as willingness-to-pay, and 
other approaches discussed above, could be used to estimate the time trade- off equivalent.   
The human burden of disease was calculated as DALYs. Incidence-based YLDs were 
calculated by multiplying the numbers of cases of disease reported by their duration and DW. The 
YLLs were calculated as the numbers of deaths and their residual life expectancy at the time of 
death. Suitable DWs from the GBD 2010 study[41] were used in all estimates. To calculate the 
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ALEs, first an estimate of the annual monetary impact of the animal diseases, including production 
losses, was made. These estimates were already published previously in several of the datasets used, 
but were updated to 2015. This was achieved by converting to US$ at the prevailing exchange rate 
at the time of the study (http://www.x-rates.com/historical) followed by a correction for the US$ 
inflation rate since the date of the estimates (http://www.usinflationcalculator.com/). This total 
monetary impact of the animal disease was then divided by the gross national per capita income 
(GNI) to obtain ALEs at 2015 values. 
ALE = monetary value of animal health losses/ GNI per person 
In all our calculations we used nominal values converted to US$ at the mean exchange rate in 2015 
to make the estimates of ALEs.  Nominal values were selected, as all the studies used current rather 
than international dollar or local currency values.  
Thus zDALY = YLL + YLD +ALE  
GNI per capita data at current dollars were according to the World Bank figures (downloaded from 
http://data.worldbank.org/indicator/NY.GNP.PCAP.CD). 
 
Results 
Table 2 gives the estimated ALEs for echinococcosis in different countries, whilst Table 3 gives the 
DALYs and incident zDALYs. The relative contribution to the zDALY from DALYs and ALEs 
varies between different countries. For echinococcosis in Iran for example, most of the burden is 
from the livestock sector. In Peru the opposite is the case. This is illustrated in Figure 1. The 
monetary losses due to echinococcosis vary from $4.4 million per year for Peru, to $144 million per 
year for Iran (Table 1). However, when adjusted for purchasing parity and converted into ALEs, 
Spain, for example, loses just 867 ALEs, compared to Kyrgyzstan which loses 4 583 ALEs (Table 
2). This is despite the fact that the gross economic loss in Spain is $25.3 million, some four times 
that of Kyrgyzstan of $5.5 million (Table 1).  
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For brucellosis in Kyrgyzstan nearly 90% of the societal burden is from animal losses (Table 
4, Figure 2). This compares to about 31% for Q fever in the Netherlands, but under 1% for 
cysticercosis in West Cameroon. In the Netherlands, Q fever had a monetary impact on animal 
health of approximately $122 million. This was more than ten times higher than the monetary 
impact of brucellosis in livestock in Kyrgyzstan. However, in terms of ALEs, there was a much 
higher impact in Kyrgyzstan with the loss of 9 333 ALEs (164 per 100 000 people) compared to 2 
571 (15.2 per 100 000 in the Netherlands). 
 
Discussion 
 DALYs, reflect only the importance of human disease or injury to society. Zoonotic diseases can 
have adverse outcomes for both human and animal subjects. We have proposed the zDALY to 
quantify this. This also takes into account time lost due to animal morbidity and mortality. As for 
the DALY, our focus in this quantification of both human and animal losses is on the impact of 
morbidity and mortality: we do not consider the wider prevention and treatment costs of ill health in 
people and animals and we restrict the burden of human disease to the DALY component. The 
essential component to include animal health losses is converting monetary losses due to animal 
disease into time lost to society. This is achieved by equating it to the time needed to earn the 
income to recover that loss. Time trade-offs are one method used to estimate the value of health 
states when calculating Quality Adjusted Life Years (QALYs)[43].  
Therefore the same concept could indeed be applied to QALY losses. However our focus is 
on the DALY as this is the most common HALY metric for quantifying burden of disease. Also, 
DALYs were originally formulated from a disease perspective, while QALYs were formulated from 
a patient perspective. As the addition of livestock losses is proposed for quantifying the disease 
burden of specific diseases, the perspective coincides with that of the DALY. 
Although time trade-offs have been used to estimate DWs for DALYs[44,45], in GBD 2010, 
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DWs for DALY calculations were developed through household surveys. These asked respondents 
paired comparison questions, in which respondents considered two hypothetical individuals with 
different, randomly selected health states and indicated which person they regarded as healthier. A 
further survey included questions about population health equivalence for a subset of 30 health 
states. In these questions, respondents were asked to compare the health benefits of different life-
saving or disease-prevention programmes to anchor disability weights to the necessary scale (from 
zero to one)[41]. It would also be possible to undertake similar household surveys to determine 
equivalences of monetary losses with health states, but these would need to be controlled for local 
income levels. Furthermore, we use monetary values of livestock losses purely as a technique to 
estimate the time trade-off to calculate the ALE. Some animals such as a treasured domestic pet or 
an animal of great religious significance may have a value to the owner far greater than its 
commercial worth. Such issues can still be addressed by household surveys to gauge how these are 
valued. The ALE could then be calculated for the respective species based on the results of such 
surveys. 
The strength of our approach is that it values different monetary losses in terms of their local 
impact. For example, in Spain the monetary loss due to echinococcosis is approximately $55 375 
per 100 000 person years. In Peru it is $14 500 per 100000 person years. However, because Peru 
has a considerably lower per capita income, there is a higher burden of ALEs in Peru (2.3 per 100 
000 person years) compared to Spain (1.9 per 100 000 person years). Thus ALEs have the desirable 
property of being linked to the actual impact of the losses felt to the population. It may be that 
ultimately an ALE is considered to be of less value than a whole life year – a person may value their 
working time at say, only half their time.  Such equivalences could be further explored and nuanced 
once the concept of the ALE has gained some traction.  A potential limitation of our approach is 
that for the ALE component our examples examine direct losses due to mortality and morbidity 
(converted to a time trade-off) and there are other aspects, such as intervention costs. However, it 
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thus remains analogous to estimating DALYs where costs of treatment or control are not included 
in the metric. Therefore comparable and analogous data must be used for estimating the ALE and 
DALY components of the zDALY. 
There have been attempts to put a monetary value on a DALY[46]. In the context of 
zoonotic disease, we propose the opposite by giving a local monetary loss due to livestock disease 
an equivalent DALY. It may be possible to extend this approach to estimating the impact of animal 
diseases that are not zoonoses. An example would be the foot and mouth disease (FMD) outbreak in 
the United Kingdom in 2001. Over 6 million animals were slaughtered resulting in approximately 
£3.1 billion ($4.5 billion) losses to agriculture and the food chain[47]. The GNI per person in the 
UK in 2001 was $26 300, so the impact in terms of ALEs would be approximately 170 000. This  
considerable number of DALY equivalents would reflect the devastation caused to UK agriculture 
during the outbreak. Another possible extension of the approach would be to set it in a wider One 
Health framework, looking at ecosystem impacts, such as the time equivalent required for an 
ecosystem to recover from damage.  
The zDALY can, like the DALY, be used in priority-setting across sectors. In cost-
effectiveness studies the cost per zDALY averted can be used to compare different interventions for 
the same disease, or more broadly to compare the cost-effectiveness of control compared to the 
cost-effectiveness of other competing public health projects. It may improve the efficiency of 
resource allocation as the zDALY accounts for the often substantial societal impact to animal health 
of zoonotic diseases. This is particularly true in marginalised communities which subsist on small 
numbers of livestock. In poor countries, diseases kill many animals. In 2009 a total of 2.1 million 
cattle and 13.1 million sheep died of disease in just three sub-Saharan African countries: Burkina 
Faso, Mali and Niger. This represented a direct loss of 5.5% of total GDP[48] . Losses from other 
livestock and indirect losses would further substantially inflate this figure. Furthermore, half of the 
world's hungry are smallholder farmers who depend on agriculture for their livelihood[49]. Thus the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
loss due to disease of an agricultural animal can have a devastating effect on such smallholders. The 
DALY does not take this into account, as the metric only analyses the burden of human disease. 
Thus the zDALY could be a valuable tool in public health economics priority setting. For example, 
data from the GBD 2010 study  would ideally “be supplemented with additional information 
regarding the impact of different conditions on the health and welfare of individuals in different 
locales”[50]. The zDALY provides such information on the impact of animal disease and could also 
potentially drive sustainable development action. By anchoring disease losses firmly in relation to 
DALYs for people and in terms of local monetary losses for animals this joint metric is clear and 
transparent to both the animal and human health constituency, while  providing an aggregate metric 
of the relative losses incurred.  
In 2011, the Disease Reference Group on Zoonoses and Marginalised Infectious Diseases 
(DRG6), convened by the Special Programme for Research and Training in Tropical Diseases 
(TDR), identified nine macro research priorities related to zoonotic diseases of marginalised 
populations[51]. One of these priorities was the development of a comprehensive methodology for 
calculating the societal burden of disease attributable to zoonoses. The zDALY metric provides a 
straightforward, practical and rigorous answer to this need. 
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Legend for Figures 
Figure 1. Top: Estimated number of  zDALYs per 100,000 population for echinococcosis in various 
countries. Bottom: proportion of  zDALY contributed by YLDs, YLLs and ALEs. 
 
Figure 2. Proportion of zDALY contributed by the standard DALY and ALE by brucellosis in the 
Kyrygz republic, Q fever in the Netherlands and cysticercosis in West Cameroon. 
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Table 1. 
Data used to estimate the zDALY for cystic echinococcosis (CE) 
 Year Animal  
Losses* 
US$ 2015 
equivalent 
GNI per capita  
2015 
Treatment-seeking 
human cases/ annum 
Non treatment- seeking human 
cases/ annum 
Iran 2010 $132 million $143 million $6 550 922 937 
Jordan 2001 $3.58 million $4.82 million $4 680 187 200 
Kyrgyzstan 2013 $5.5 million $5.6 million $1 170 884 1 226 
Peru 2007 $3.85 million $4.40 million $6 130 2 890 4 380 
Spain 2005 €15.5million $25.8 million $28 530 208 208 
Tunisia 2000 $8.38 million $11.45 million $3 980 1 339 1 127 
* As reported in [25-30] 
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Table 2 
Animal loss equivalents (ALEs): CE 
 Human population ALEs ALEs/100 000 person years 
Iran 79.1 million 21 832 27.6 
Jordan 7.59 million 1 030 13.5 
Kyrgyzstan 5.94 million 4 795 80.7 
Peru 31.8 million 628 2.0 
Spain 46.1 million 904 2.0 
Tunisia 11.3 million 2 299 20.3 
 
 
Table 3 
Burden of disease for CE in terms of DALYs and zDALYs 
 YLDs YLLs DALYs DALYs/100 000 
person years 
ALEs/100 000 
person years 
zDALY/100 000 
person years 
Iran 537 1 198 1 766 2.23 27.6 29.8 
Jordan 113 250 368 4.85 13.5 18.4 
Kyrgyzstan 573 1 258 1 845 31.1 80.7 112 
Peru 1 943 4 185 6 229 19.6 2.0 21.6 
Spain 126 271 402 0.87 1.0 1.87 
Tunisia 758 1 689 2 477 21.9 20.3 42.2 
Source: data from WHO Foodborne Disease Burden Epidemiology Reference Group(FERG)[42] 
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Table 4  
Burden of other diseases 
Country Disease Animal 
losses 
US$ 2015 
Equivalents 
Human 
cases 
DALYs DALYs/ 
100 000 
person years 
ALEs ALEs/ 
100 000 
person years 
zDALYs/ 
100 000 
person 
years 
Kyrgyzstan+ Brucellosis $10 million $11.8 million 3 350  1 075 18 10 085 170 188 
Netherlands*  Q fever €85million $124 million 4 107  5797 34 2537 15 49 
West Cameroon# Cysticercosis €478 838 $794 842 18 268  45 838 9 050 602 12 9 061 
 
+DALY estimate from FERG data[42]  (DALYs per case). 
*Q fever outbreak – data from[34-36] , duration of outbreak 2007-2011 
#Data from[39].  
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